Take a breath. If you just read old search results saying Paroxysmal Nocturnal Hemoglobinuria (PNH) has a 10- to 15-year life expectancy, close those tabs. Those numbers come from before 2007, when targeted therapy did not exist. Today, with modern C5 and proximal complement inhibitors, life expectancy for PNH patients matches age-matched people without the disease.
Why does a flow cytometry lab report show a 68% PNH clone in granulocytes but only an 18% clone in red blood cells? And why do 25% to 35% of patients on intravenous C5 inhibitors normalize their LDH yet still feel exhausted with a hemoglobin of 9.1 g/dL? Select where you are in your PNH journey below to go straight to the answers and tools built for your next hematology visit.
See why pre-2007 survival statistics are obsolete and how modern complement blockade restores a normal 15-year survival curve.
View Survival & Clone Atlas ↓Enter your Granulocyte FLAER %, RBC CD59 %, LDH, and Hemoglobin for a plain-English bedside translation and printable doctor visit sheet.
Open Side-by-Side Lab Consult ↓Understand why extravascular hemolysis (EVH) happens on C5 blockade and filter all 6 approved IV, SC, and oral complement inhibitors.
Compare All 6 Therapies ↓Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired somatic PIGA stem cell disorder in which blood cells lack glycosylphosphatidylinositol (GPI) anchor proteins CD55 and CD59. Unchecked complement activation lyses red blood cells and triggers venous thrombosis. Modern terminal C5 and proximal C3, Factor B, and Factor D inhibitors restore near-normal life expectancy.
Click one of the 4 real-world patient examples below or enter your own lab numbers on the left. On the right, your bedside translation updates live with your LDH multiple gauge, granulocyte vs. RBC clone discrepancy explanation, C3d extravascular hemolysis check, and a printable 3-question sheet for your hematologist.
Active Intravascular Hemolysis (LDH >= 1.5x ULN & clone >= 10%): Free hemoglobin is actively scavenging nitric oxide (driving fatigue and thrombotic risk). This meets international clinical thresholds to start or optimize terminal C5 or proximal complement blockade.
Clone Discrepancy Explained: Your granulocyte clone (68%) is much higher than your measured RBC clone (18%). Granulocytes show your true bone marrow PNH stem cell burden; the RBC number looks artificially low because fragile Type III red cells burst early or are diluted by transfusions.
Before 2007, unchecked intravascular hemolysis and venous blood clots limited median survival to 10 to 15 years. Today, blocking the complement cascade restores 15-year survival to match age-matched general population controls, while protecting fragile Type III red blood cells from premature lysis:
High-sensitivity flow cytometry (sensitivity down to 0.01%) frequently detects minute GPI-deficient clones in patients with acquired aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS). At <1% clone size, serum LDH is normal (<1.5x ULN) and clinical intravascular hemolysis is absent. Finding a minor PNH clone is actually a reassuring biomarker that predicts higher response rates to immunosuppressive therapy (ATG + cyclosporine).
Next Step: Repeat high-sensitivity flow cytometry every 6 to 12 months; complement inhibitor therapy is not needed at this stage. Read our AA & MDS Overlap Guide.
Patients with a 1% to 10% granulocyte clone typically fall into the IPIG category of PNH in the setting of another specified bone marrow disorder. Low blood counts (platelets, neutrophils, or anemia) are driven primarily by marrow hypoplasia rather than complement-mediated red cell lysis. However, clones can expand as the bone marrow recovers after immunosuppressive therapy.
Next Step: Track LDH, reticulocyte count, and haptoglobin every 3 to 6 months. Treat underlying marrow failure first unless LDH rises above 1.5x ULN with hemolytic symptoms. See Flow Cytometry Decoder.
In the 10% to 49% clone range, symptoms depend heavily on the proportion of Type II (partially CD59-deficient) vs. Type III (completely CD59-deficient) red cells and whether active intravascular hemolysis is present (LDH >= 1.5x upper limit of normal). Patients with Type III dominance, LDH >= 1.5x ULN, symptomatic anemia, esophageal spasms, or any prior blood clot benefit from complement inhibition.
Next Step: Compare All 6 Approved Complement Inhibitors and review thrombosis warning signs.
| Diagnostic Parameter | Typical Untreated Finding | Why This Happens in Your Blood | Goal on Complement Therapy |
|---|---|---|---|
| Granulocyte & Monocyte FLAER | 50% to 99% GPI-deficient | True measure of PIGA stem cell dominance in bone marrow (white cells do not lyse from complement). | Clone % stays high; therapy protects red blood cells from bursting rather than erasing the marrow clone. |
| RBC CD59 (Type III) Clone | Often 15% to 45% (falsely low) | Type III RBCs lack CD59 entirely and burst inside blood vessels (C5b-9 MAC) or are diluted by transfusions. | Type III RBC % climbs toward your granulocyte % once therapy keeps your red blood cells alive! |
| Serum LDH (Lactate Dehydrogenase) | 3.0x to 10.0x ULN (>750 to 2,500+ U/L) | Direct marker of intravascular hemolysis (IVH) and cell-free hemoglobin spilling into plasma. | <1.5x ULN (normal or near-normal), cutting venous blood clot risk by >85%. |
| Reticulocytes & Direct Coombs (C3d) | Reticulocytes >120 x 10^9/L; Coombs negative pre-treatment | Bone marrow working overtime. On C5 inhibitors, surviving RBCs can accumulate surface C3d tags. | If Hb stays <10.5 g/dL with high reticulocytes & C3d+ on C5 therapy, discuss proximal C3/Factor B/D blockade. |
Why does terminal C5 blockade stop intravascular hemolysis yet leave extravascular anemia in 25% to 35% of patients? Filter all 6 FDA/EMA/NMPA-approved complement inhibitors below by what matters most to your daily life:
Every guide is written in warm, plain language, anchored to peer-reviewed trials and guidelines, and mirrored across English, Spanish, and Simplified Chinese.
Why granulocyte FLAER clone size differs from RBC clone size, Type I/II/III red cell populations, and why chronic hemolysis causes the renal cortical hemosiderosis rim sign on CT and MRI.
Interactive head-to-head comparison of Ravulizumab (Ultomiris), Eculizumab (Soliris & biosimilars), Pegcetacoplan (Empaveli), Iptacopan (Fabhalta), Danicopan (Voydeya), and Crovalimab (Piasky).
Managing nitric-oxide-depletion fatigue, why unmonitored iron supplementation triggers hemolytic crises when starting therapy, travel checklists, and MenACWY + MenB schedules.
Budd-Chiari hepatic vein thrombosis, portal/mesenteric clots, cerebral venous sinus thrombosis, and how to manage infection-triggered breakthrough hemolysis (BTH).
Why 40% to 50% of acquired aplastic anemia patients harbor a PNH clone, the autoimmune T-cell escape mechanism, and sequencing ATG + cyclosporine + eltrombopag with complement blockade.
Why estrogen contraception is contraindicated, NEJM evidence for eculizumab safety in pregnancy, LMWH anticoagulation through 6 weeks postpartum, and pre-surgical dosing.
Comparing $450,000-$550,000/yr US list prices, FDA/EMA eculizumab biosimilars (Bkemv, Epysqli), UK NHS national commissioning, Latin America, and China NRDL reimbursement + HSCT centers.
Concordance of historical PNH Support Group resources, verified international patient advocacy organizations (AAMDSIF, PNH Support UK, HPN Espana, AAMAC), and editorial methodology.
Clear, compassionate answers grounded in ASH guidelines, IPIG consensus, and Phase 3 complement inhibitor clinical trials.
No. PNH is not leukemia or a malignant cancer, and it never metastasizes to solid organs. It is a benign acquired clonal disorder of hematopoietic stem cells caused by a somatic mutation in the PIGA gene. However, because PNH shares deep bone marrow biology with aplastic anemia and myelodysplastic syndrome (MDS), a small minority of patients (roughly 2% to 5% over 10 years) can evolve into MDS or acute myeloid leukemia, requiring regular complete blood count monitoring.
Clinical source: Parker et al., Blood 2005 (IPIG Consensus) · See AA & MDS Overlap.
Laboratories diagnose PNH using high-sensitivity multiparameter flow cytometry on peripheral blood. In red blood cells, testing measures the GPI-anchored complement regulators CD55 and CD59 to classify cells into Type I (normal), Type II (partial deficiency), and Type III (complete deficiency). In white blood cells (granulocytes and monocytes), laboratories combine FLAER (fluorescently labeled inactive aerolysin, which binds directly to the GPI anchor) with lineage markers such as CD15, CD24, CD14, and CD64.
Clinical source: Borowitz et al., Cytometry Part B 2010 · See Flow Cytometry Decoder.
Before the approval of eculizumab in 2007, median survival after a PNH diagnosis was 10 to 15 years, with venous thrombosis accounting for up to two-thirds of deaths. Today, long-term registry studies from the UK, US, and Europe demonstrate that PNH patients treated with terminal C5 inhibitors (eculizumab or ravulizumab) or proximal complement inhibitors who do not have severe underlying bone marrow failure achieve a life expectancy matching age-matched healthy controls.
Clinical source: Kelly et al., Blood 2011; Kulasekararaj et al., Ann Hematol 2025.
Although the disease was named in the 19th century for dark morning urine (caused by mild respiratory acidosis during sleepenhancing complement activation and concentrated overnight urine), chronic low-grade intravascular hemolysis occurs 24 hours a day. Roughly 70% to 75% of newly diagnosed patients present with crushing fatigue, anemia, smooth muscle spasms, or unexplained thrombosis rather than visible macroscopic hemoglobinuria.
Clinical source: Brodsky, NEJM 2014 / Blood 2021 Review · See Living With PNH.
Show this card immediately to the Emergency Department triage nurse and attending physician if you have Paroxysmal Nocturnal Hemoglobinuria (PNH) and develop fever >= 38.0°C (100.4°F), severe abdominal pain, or sudden headache.
Patients on terminal C5 (Ultomiris, Soliris, Piasky) or proximal C3 / Factor B / Factor D inhibitors (Empaveli, Fabhalta, Voydeya) carry a >1,000x risk of fulminant Neisseria meningitidis and encapsulated sepsis. Draw STAT blood cultures and administer empiric IV Ceftriaxone 2g immediately. Do NOT delay antibiotics for lumbar puncture or imaging.
PNH causes venous clots in unusual sites: hepatic veins (Budd-Chiari syndrome), portal/mesenteric veins, and cerebral dural venous sinuses. Order urgent Doppler ultrasound, CT venography, or MR venography plus STAT LDH, CBC, reticulocytes, and creatinine.
Never stop oral Fabhalta (iptacopan), Voydeya (danicopan), SC Empaveli, or IV Ultomiris/Soliris during hospitalization. Stopping therapy exposes accumulated Type III PNH red blood cells to catastrophic rebound breakthrough hemolysis and thrombosis.
If infection triggers dark cola-colored urine and a sharp LDH surge (>2x ULN), contact the on-call hematologist immediately for early/supplemental complement inhibitor dosing, aggressive IV hydration, and prophylactic/therapeutic LMWH anticoagulation.